At the molecular level, P53 mutation likely suppresses OATP1B3 through two synergistic pathways: Genetic mutual exclusivity: P53 mutation and Wnt/β-catenin pathway activation (a key positive regulator of OATP1B3) are rarely co-occurring in HCC [29]. Here, SLCO1B3 is linked to hepatocellular carcinoma.